纽勤 2026年季度报告

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2025.or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission file number 0-17988 (Exact name of registrant as specified in its charter) 38-2367843(IRS EmployerIdentification Number) 620 Lesher PlaceLansing, Michigan 48912(Address of principal executive offices, including zip code)(517) 372-9200(Registrant’s telephone number, including area code)SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to suchfiling requirements for the past 90 days.YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐Emerging growth company☐ Accelerated filerSmaller Reporting Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):YES☐NO☒As of November 30, 2025 there were 217,525,981 shares of Common Stock outstanding. NEOGEN CORPORATIONTABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1.Interim Condensed Consolidated Financial Statements (unaudited)2CondensedConsolidated Balance Sheets – November 30, 2025 and May 31, 20252CondensedConsolidated Statements of Operations – Three and six months ended November 30, 2025and November 30, 20243CondensedConsolidated Statements of Comprehensive (Loss) Income – Three and six months endedNovember 30, 2025 and November 30, 20244CondensedConsolidated Statements of Equity – Three and six months ended November 30, 2025 andNovember 30, 20245CondensedConsolidated Statements of Cash Flows – Six months ended November 30, 2025 andNovember 30, 20246Notes to Interim CondensedConsolidated Financial Statements – November 30, 20257Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures27 PART II. OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 5.Other InformationItem 6.Exhibits SIGNATURES CEO CertificationCFO CertificationSection 906 Certification Neogen CorporationCondensed Consolidated Statements of Equity (unaudited)(in thousands, except shares) Neogen CorporationCondensed Consolidated Statements of Cash Flows (unaudited)(in thousands) NEOGEN CORPORATIONNOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(Dollar amounts in thousands except shares) 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION DESCRIPTION OF BUSINESS Neogen Corporation and subsidiaries ("Neogen," "we," "our" or the "Company") develop, manufacture and market a diverse line ofproducts and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits andcomplementary products (e.g., culture media) sold to food producers and processors to detect dangerous and/or unintendedsubstances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, geneticmodifications, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns. Themajority of the test kits are disposable, single-use, immunoassay and DNA detection products that rely on proprietary antibodiesand RNA and DNA testing methodologies to produce rapid and accurate test results. Our expanding line of food safety productsalso includes advanced software systems that help testers objectively analyze and store, as well as perform analysis on their resultsfrom multiple locations over extended periods. Neogen’s Animal Safety segment is engaged in the deve